QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



SCHEDULE 14D-9
(Rule 14d-101)



Solicitation/Recommendation Statement under Section 14(d)(4)
of the Securities Exchange Act of 1934

(Amendment No. 1)

NuPathe Inc.
(Name of Subject Company)

NuPathe Inc.
(Names of Persons Filing Statement)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

67059M100
(CUSIP Number of Class of Securities)



Michael F. Marino, Esq.
Senior Vice President, General Counsel and Secretary
NuPathe Inc.
7 Great Valley Parkway, Suite 300
Malvern, Pennsylvania 19355
(610) 232-0800
(Name, address and telephone numbers of person authorized to receive
notices and communications on behalf of the persons filing statement)



With copies to:
Michael N. Peterson, Esq.
Morgan, Lewis & Bockius LLP
1701 Market Street
Philadelphia, Pennsylvania 19103
(215) 963-5000



o
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

   


Purpose of Amendment

        This Amendment No. 1 (this "Amendment") amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 of NuPathe Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") on December 23, 2013 (the "Schedule 14D-9"). The Schedule 14D-9 relates to the tender offer by DM Merger Sub Inc., a Delaware corporation ("Purchaser") and an indirect, wholly owned subsidiary of Endo Health Solutions Inc., a Delaware corporation ("Parent"), to purchase any and all of the issued and outstanding shares of the Company's common stock, par value $0.001 per share (the "Shares"), at a price per Share of $2.85 per Share, net to the seller in cash (less any required withholding taxes and without interest), plus contractual rights to receive up to an additional $3.15 per Share in contingent cash consideration payments (less any required withholding taxes) payable in the future upon achievement of certain milestones related to ZECUITY, sumatriptan iontophoretic delivery system, the Company's primary product, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 23, 2013 (as amended or supplemented from time to time, the "Offer to Purchase") and in the related Letter of Transmittal (as amended or supplemented from time to time, the "Letter of Transmittal" and, together with the Offer to Purchase, the "Offer") filed by Parent and Purchaser with the SEC on December 23, 2013. The Offer is described in a Tender Offer Statement on Schedule TO-T (as amended or supplemented from time to time, the "Schedule TO"), filed by Parent and Purchaser with the SEC on December 23, 2013. The Offer to Purchase and Letter of Transmittal are filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Schedule TO.

        Except as otherwise set forth below, the information set forth in the Schedule 14D-9 remains unchanged and is incorporated by reference as relevant to the items in this Amendment. Capitalized terms used and not defined herein shall have the meanings assigned to such terms in the Schedule 14D-9. This Amendment is being filed to reflect certain updates as reflected below:

Item 8.    Additional Information

        Item 8 ("Additional Information") of the Schedule 14D-9 is hereby amended and supplemented by adding the following information set forth below at the end of Item 8(e) under the heading "Litigation" with the following:

2


3


Item 9.    Exhibits

        Item 9 ("Exhibits") of the Schedule 14D-9 is hereby amended and supplemented by adding the following exhibits:

Exhibit No.   Description
(a)(5)(F)   Complaint filed by Charlotte Gilbert in the Court of Chancery of the State of Delaware on December 27, 2013 (incorporated by reference to Exhibit (a)(5)(F) to the Schedule TO as filed on Schedule TO-T/A on December 30, 2013).

(a)(5)(G)

 

Complaint filed by Ricardo Morant in the Court of Chancery of the State of Delaware on December 27, 2013 (incorporated by reference to Exhibit (a)(5)(G) to the Schedule TO as filed on Schedule TO-T/A on December 30, 2013).

(a)(5)(H)

 

Complaint filed by Richard Affronte in the Court of Common Pleas of Chester County, Pennsylvania on December 20, 2013 (incorporated by reference to Exhibit (a)(5)(H) to the Schedule TO as filed on Schedule TO-T/A on December 30, 2013).

4



SIGNATURE

        After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    NUPATHE INC.

Date: December 30, 2013

 

By:

 

/s/ ARMANDO ANIDO

        Name:   Armando Anido
        Title:   Chief Executive Officer

5




QuickLinks

SIGNATURE